A Phase 1 Absolute Bioavailability Study For Oral Crizotinib In Healthy Volunteers
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This study will be an open-label, randomized, 2-period, 2-treatment, 2-sequence, cross-over
single-dose study to test the absolute bioavailability of oral crizotinib formulation to IV
formulation in healthy adult volunteers. Fourteen (14) subjects will be enrolled to obtain at
least 12 evaluable subjects who complete the study. Each subject will receive two treatments
(A and B) with a washout period of at least 14 days between each treatment.